denileukin diftitox
denileukin diftitox is a biological therapy with 20 clinical trials. Historical success rate of 82.4%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
14
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
73.7%
14 of 19 finished
26.3%
5 ended early
0
trials recruiting
20
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Clinical Trials (20)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
Phase II Trial of Ontak With Metastatic Melanoma
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Denileukine Diftitox for Relapsed ALCL
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
All 20 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 20